Global Hereditary Cancer Testing Market Size By Type (Biopsy, Imaging), By Application (Hospital, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Hereditary Cancer Testing Market was valued at USD 5.6 billion in 2023 and is projected to reach USD 12.3 billion by 2031, growing at a CAGR of 10.3% during the forecast period from 2023 to 2031. The market is witnessing robust growth driven by rising awareness of genetic predisposition to cancer, increasing demand for early cancer detection, advancements in genomic technologies, and the integration of personalized medicine into oncology practices.

Hereditary cancer testing plays a pivotal role in identifying mutations in genes associated with inherited cancer syndromes. With cancer incidences steadily rising and individuals seeking proactive health management, demand for accessible and accurate hereditary testing is surging worldwide. As healthcare systems increasingly focus on preventive care and targeted therapies, this market is becoming an integral part of oncology diagnostics.

Drivers:

Rising Awareness of Genetic Risk Factors:

Public and clinical awareness of the genetic basis of cancers such as breast, ovarian, colorectal, and prostate cancer is growing rapidly. Campaigns and educational programs by health organizations are fueling the demand for hereditary testing.

Advancements in Genomic Technologies:

Next-generation sequencing (NGS) and multiplex genetic panels have significantly reduced testing costs and turnaround times while improving accuracy. These advancements are driving wider clinical adoption.

Increased Demand for Personalized Medicine:

Oncology is increasingly shifting toward individualized treatment strategies. Hereditary cancer testing enables tailored therapies, especially in BRCA1/2 mutation carriers and other high-risk patient groups.

Restraints:

High Cost and Limited Reimbursement Policies:

Although prices have decreased, the cost of comprehensive genetic testing remains high in some regions. Limited insurance coverage or reimbursement acts as a deterrent for patients, especially in developing economies.

Ethical and Privacy Concerns:

Concerns regarding genetic data privacy, potential discrimination, and the psychological impact of results may limit the willingness of individuals to undergo testing.

Opportunity:

Expansion of Direct-to-Consumer (DTC) Testing Services:

Companies offering at-home hereditary cancer test kits are experiencing increased traction, especially in North America and Europe. The accessibility of these services opens new growth avenues.

Integration with Electronic Health Records (EHRs):

Efforts to integrate genetic data into EHRs for holistic patient care management present new opportunities for market expansion and enhanced clinical utility.

Rising Focus in Emerging Markets:

Governments and private players are increasing investments in genetic research and diagnostics in Asia-Pacific and Latin America, offering high-growth potential.

Market by System Type Insights:

By system type, the Panel Testing segment held the largest share in 2023, owing to its ability to assess multiple genes simultaneously. These panels are commonly used in clinical settings for evaluating hereditary risks for cancers such as breast, ovarian, pancreatic, and colorectal cancers. The Single-Gene Testing segment remains relevant for targeted mutation analysis, especially in family members of known carriers.

Market by End-use Insights:

In terms of end-use, Hospitals & Diagnostic Laboratories dominated the market in 2023, accounting for more than 50% of the revenue share. This dominance is driven by the integration of hereditary cancer testing into standard oncology workflows and the availability of infrastructure to support complex diagnostics. Meanwhile, the Direct-to-Consumer segment is expected to exhibit the highest CAGR during the forecast period due to the rise of at-home test kits and digital health platforms.

Market by Regional Insights:

North America held the largest market share in 2023, supported by strong regulatory frameworks, favorable reimbursement policies, and the presence of major market players. Europe follows closely due to rising awareness and government support for genetic screening programs. The Asia-Pacific region is projected to register the fastest growth rate, propelled by expanding healthcare access, growing medical tourism, and increasing cancer prevalence.

Competitive Scenario:

Key players in the Global Hereditary Cancer Testing Market include Myriad Genetics, Inc., Invitae Corporation, Illumina, Inc., Ambry Genetics (a Konica Minolta company), GeneDx (Sema4), Color Health, Inc., Fulgent Genetics, PreventionGenetics, and Natera, Inc. These companies are actively pursuing strategic collaborations, expanding test portfolios, and leveraging AI to enhance genetic interpretation.

Notable Developments:

2023: Invitae Corporation launched a low-cost genetic testing initiative to increase access to hereditary cancer testing in underserved populations.

2024: Myriad Genetics introduced a next-generation panel testing service integrated with polygenic risk scoring for breast and ovarian cancers.

2025: Natera announced AI-enhanced hereditary cancer testing algorithms to improve mutation detection sensitivity in low-quality DNA samples.

Scope of Work – Global Hereditary Cancer Testing Market

Report Metric Details

Market Size (2023) USD 5.6 billion

Projected Market Size (2031) USD 12.3 billion

CAGR (2023–2031) 10.3%

Key Segments By System Type (Panel Testing, Single-Gene Testing), By End-Use

Growth Drivers Rising awareness of genetic risk, Advancements in genomic technology

Opportunities DTC testing expansion, Emerging markets, EHR integration

FAQs:

1) What is the current market size of the Global Hereditary Cancer Testing Market?

The market was valued at USD 5.6 billion in 2023.

2) What is the major growth driver of the Global Hereditary Cancer Testing Market?

The major growth driver is the rising awareness of genetic predispositions and the increasing adoption of personalized medicine in oncology.

3) Which is the largest region during the forecast period in the Global Hereditary Cancer Testing Market?

North America is the largest region, supported by robust infrastructure and regulatory support.

4) Which segment accounted for the largest market share in the Global Hereditary Cancer Testing Market?

Panel Testing accounted for the largest market share in 2023.

5) Who are the key market players in the Global Hereditary Cancer Testing Market?

Key players include Myriad Genetics, Invitae Corporation, Illumina, Ambry Genetics, and Natera.